Chromogranin A (CgA) in the Diagnosis and Monitoring of Patients with Gastroenteropancreatic (GEP) Neuroendocrine Tumors (NET): A Single-Institution Experience

#418

Introduction: Gastroenteropancreatic neuroendocrine tumors (GEP NET) are heterogeneous neoplasms with different malignancy. Plasma chromogranin A (CgA) may play an important role in predicting outcome.

Aim(s): To evaluate the clinical utility of CgA in diagnosing and monitoring GEP NET patients.

Materials and methods: One-hundred and eighty-one GEP NET patients were diagnosed and followed-up from 1995 to 2010: 81 had pancreatic NET, 31 gastric, 18 duodenal, 37 ileal, three colonic and 11 rectal. 105 were NET G1, 64 NET G2 and 12 NEC G3, according to WHO 2010 classification; 81 were classified in stage I, 14 in stage II, 17 in stage III and 69 in stage IV. CgA values were collected at diagnosis and during follow-up. Surgical interventions, medical treatment, comorbidities, causes of death, and survival were evaluated.

Conference: 9th Annual ENETSConcerence (2012)

Presenting Author:

Authors: Massironi S, Rossi R, Spampatti M, Casazza G, Conte D,

Keywords: CgA, GEP-NET,

To read the full abstract, please log into your ENETS Member account.